Sara N Glick1,2, Kathryn S Klein3, Joe Tinsley2, Matthew R Golden1,2. 1. Division of Allergy and Infectious Diseases, School of Medicine, University of Washington, Seattle, Washington. 2. Public Health-Seattle & King County, HIV/STD Program, Seattle, Washington. 3. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
Abstract
BACKGROUND AND OBJECTIVES: Methamphetamine use is increasing in the United States, potentially including the simultaneous injection of methamphetamine with heroin (goofball). We compared demographic, behavioral, contextual, and health factors among people who inject drugs (PWID) in the Seattle area and who reported that their main drug was goofball, heroin, or methamphetamine. METHODS: We used data from 2017 and 2019 cross-sectional surveys of clients at Public Health-Seattle & King County's syringe services program (N = 792). RESULTS: Among PWID participants, 55.3% reported using goofball in the last 3 months, and the proportion reporting goofball as their main drug doubled between 2017 (10.3%) and 2019 (20.1%, P < .001). The goofball group had the highest proportions of people who were aged less than 30, women, homeless or unstably housed, and recently incarcerated. PWID whose main drug was goofball reported considerable health risks and morbidity. Witnessing an opioid overdose was most commonly reported by participants whose main drug was goofball. This group also reported naloxone possession and use in an overdose situation more than other participants. The majority of participants were interested in reducing or stopping their opioid and stimulant use. DISCUSSION AND CONCLUSIONS: Among PWID, using goofball as a main drug doubled over 2 years and was characterized by contextual and individual factors that increase the risk of morbidity and mortality. SCIENTIFIC SIGNIFICANCE: This is the first study to characterize goofball use as a main drug. Clinical and public health efforts to diminish morbidity associated with opioid use need to integrate interventions that address the co-use of methamphetamine. (Am J Addict 2020;00:00-00).
BACKGROUND AND OBJECTIVES: Methamphetamine use is increasing in the United States, potentially including the simultaneous injection of methamphetamine with heroin (goofball). We compared demographic, behavioral, contextual, and health factors among people who inject drugs (PWID) in the Seattle area and who reported that their main drug was goofball, heroin, or methamphetamine. METHODS: We used data from 2017 and 2019 cross-sectional surveys of clients at Public Health-Seattle & King County's syringe services program (N = 792). RESULTS: Among PWID participants, 55.3% reported using goofball in the last 3 months, and the proportion reporting goofball as their main drug doubled between 2017 (10.3%) and 2019 (20.1%, P < .001). The goofball group had the highest proportions of people who were aged less than 30, women, homeless or unstably housed, and recently incarcerated. PWID whose main drug was goofball reported considerable health risks and morbidity. Witnessing an opioid overdose was most commonly reported by participants whose main drug was goofball. This group also reported naloxone possession and use in an overdose situation more than other participants. The majority of participants were interested in reducing or stopping their opioid and stimulant use. DISCUSSION AND CONCLUSIONS: Among PWID, using goofball as a main drug doubled over 2 years and was characterized by contextual and individual factors that increase the risk of morbidity and mortality. SCIENTIFIC SIGNIFICANCE: This is the first study to characterize goofball use as a main drug. Clinical and public health efforts to diminish morbidity associated with opioid use need to integrate interventions that address the co-use of methamphetamine. (Am J Addict 2020;00:00-00).
Authors: Alasdair M Barr; William J Panenka; G William MacEwan; Allen E Thornton; Donna J Lang; William G Honer; Tania Lecomte Journal: J Psychiatry Neurosci Date: 2006-09 Impact factor: 6.186
Authors: John M Roll; Nancy M Petry; Maxine L Stitzer; Mary L Brecht; Jessica M Peirce; Michael J McCann; Jack Blaine; Marilyn MacDonald; Joan DiMaria; Leroy Lucero; Scott Kellogg Journal: Am J Psychiatry Date: 2006-11 Impact factor: 18.112
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Grant Colfax; Thomas J Coates; Marla J Husnik; Yijian Huang; Susan Buchbinder; Beryl Koblin; Margaret Chesney; Eric Vittinghoff Journal: J Urban Health Date: 2005-02-28 Impact factor: 3.671
Authors: Lindsay M Jenkins; Caleb J Banta-Green; Charles Maynard; Susan Kingston; Michael Hanrahan; Joseph O Merrill; Phillip O Coffin Journal: J Urban Health Date: 2011-02 Impact factor: 3.671
Authors: W Ling; C Charuvastra; J F Collins; S Batki; L S Brown; P Kintaudi; D R Wesson; L McNicholas; D J Tusel; U Malkerneker; J A Renner; E Santos; P Casadonte; C Fye; S Stine; R I Wang; D Segal Journal: Addiction Date: 1998-04 Impact factor: 6.526
Authors: Tarlise Townsend; David Kline; Ariadne Rivera-Aguirre; Amanda M Bunting; Pia M Mauro; Brandon D L Marshall; Silvia S Martins; Magdalena Cerdá Journal: Am J Epidemiol Date: 2022-03-24 Impact factor: 5.363
Authors: Christopher M Jones; Debra Houry; Beth Han; Grant Baldwin; Alana Vivolo-Kantor; Wilson M Compton Journal: Ann N Y Acad Sci Date: 2021-09-24 Impact factor: 6.499
Authors: Lauren K Whiteside; Ly Huynh; Sophie Morse; Jane Hall; William Meurer; Caleb J Banta-Green; Hannah Scheuer; Rebecca Cunningham; Mark McGovern; Douglas F Zatzick Journal: J Subst Abuse Treat Date: 2021-11-24
Authors: Jaime Walters; Lea Busy; Christopher Hamel; Kelsi Junge; Timothy Menza; Jaxon Mitchell; Taylor Pinsent; Kim Toevs; Jennifer Vines Journal: AIDS Behav Date: 2021-11-10
Authors: Brittany D Rhed; Robert W Harding; Charles Marks; Katherine T Wagner; Phillip Fiuty; Kimberly Page; Karla D Wagner Journal: Front Psychiatry Date: 2022-03-28 Impact factor: 5.435
Authors: Alison M Beieler; Jared W Klein; Elenore Bhatraju; Matthew Iles-Shih; Leslie Enzian; Shireesha Dhanireddy Journal: Open Forum Infect Dis Date: 2021-05-29 Impact factor: 3.835